{"id":136421,"date":"2026-09-25T18:13:18","date_gmt":"2026-09-25T18:13:18","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/136421\/"},"modified":"2026-09-25T18:13:18","modified_gmt":"2026-09-25T18:13:18","slug":"deals-on-generic-versions-of-roche-flu-drug-aimed-at-preparing-for-pandemic","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/136421\/","title":{"rendered":"Deals on generic versions of Roche flu drug aimed at preparing for pandemic"},"content":{"rendered":"<p class=\"author-bio\">Ed\u2019s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning <a href=\"https:\/\/www.statnews.com\/signup\/pharmalittle\/\" rel=\"nofollow noopener\" target=\"_blank\">Pharmalittle newsletter<\/a> and the afternoon <a href=\"https:\/\/www.statnews.com\/signup\/pharmalot\/\" rel=\"nofollow noopener\" target=\"_blank\">Pharmalot newsletter<\/a>.<\/p>\n<p class=\"wp-block-paragraph\">With an eye toward pandemic preparedness, a U.N.-backed agency  has signed sub-licensing deals with 11 manufacturers to develop and manufacture generic versions of a Roche influenza treatment.<\/p>\n<p class=\"wp-block-paragraph\">Under the agreements, brokered by the Medicines Patent Pool, the companies can develop, manufacture, and supply Xofluza in 129 countries, covering nearly all low- and middle-income countries. The manufacturers will also have access to technical data, reference products for bioequivalence studies, and other support intended to help with regulatory approval in those countries.<\/p>\n<p class=\"wp-block-paragraph\">This marks the latest effort to widen access for a needed medication to poor countries, a goal that has often required the pharmaceutical industry to balance its financial priorities with ensuring its medicines can be affordably obtained by the largest number of patients possible.<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/09\/1790359998_412_stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" rel=\"nofollow noopener\" target=\"_blank\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Ed\u2019s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He&hellip;\n","protected":false},"author":2,"featured_media":136422,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[16893,22784,337,3714,134,339],"class_list":["post-136421","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-generics","tag-infectious-diseases","tag-pharmaceuticals","tag-public-health","tag-roche","tag-stat"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117333040176860824","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/136421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=136421"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/136421\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/136422"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=136421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=136421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=136421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}